Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles
Authors:
- Monique H MochtarMMMonique H Mochtar
- Fulco Van der VeenFVFulco Van der Veen
- Manon ZiechMZManon Ziech
- Madelon van WelyMWMadelon van Wely
- Anna MustersAMAnna Musters
- 18 April 2007
- reference entry
- Published by Wiley
- No. 2,p. CD005070
Abstract
During in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatment cycles, controlled ovarian hyperstimulation (COH) is performed with recombinant follicle stimulating hormone (rFSH) in combination with a gonadotrophin‐releasing hormone (GnRH) analogue for the prevention of premature luteinizing hormone (LH) surges. The use of GnRH analogues however deprives the growing follicles of LH. The effectiveness of co‐administrating rLH to rFSH for COH is at present unclear. To compare the effectiveness and safety of a combination of recombinant LH and recombinant FSH with recombinant FSH alone in COH protocols in (IVF or ICSI followed by embryo transfer (ET). We searched the MDSG Group Specialised Register (searched up to Nov 2006) and CENTRAL, MEDLINE and EMBASE (1980 to November 2006) and reference lists of articles. Randomised controlled trials comparing COH with rFSH alone or in combination with rLH in IVF/ICSI were included. Three review authors independently assessed trial quality and extracted data. We sought additional information if necessary. Fourteen trials involving 2612 women were included. Eleven trials involving 2396 women used a GnRH agonist .There was no evidence of a statistical difference in live birth rate reported in two trials (OR 1.51, 95% CI 0.79 to 2.87). There was no evidence of a statistical difference in clinical pregnancy rates reported in seven trials OR 1.15, 95% CI 0.91 to 1.45. There was no evidence of a statistical difference or in ongoing pregnancy rates seven trials OR 1.22, 95% CI 0.95 to 1.56. Three trials used a GnRH antagonist. No data on live birth rates was available. There was no evidence of a statistical difference in clinical pregnancy rates (one trial: OR 0.79, 95% CI 0.26 to 2.43) or in ongoing pregnancy rates (two trials: OR 0.83, 95% CI 0.39 to 1.80) comparing both groups. The pooled pregnancy estimates of trials including only poor responders showed significant increase in pregnancy rate, in favour of co‐administrating rLH (three trials: OR 1.85, 95% CI 1.10 to 3.11) There was no evidence of a statistical difference in pregnancy outcomes when rLH was used. Nevertheless, further large RCTs should be undertaken in long GnRH agonist down regulation protocols, since all pooled pregnancy estimates, although not statistically different probably due to the small numbers, point towards a beneficial effect of co‐treatment with rLH, in particular with respect to pregnancy‐loss and poor‐responders. 用於在輔助生殖週期中進行卵巢控制性超促排卵之重組促黃體素 (recombinant Luteinizing Hormone;rLH) 重組性促黃體素用於人工生殖週期中控制性超促排卵的情形 在體外受精 (in vitro fertilization;IVF) /精蟲卵質內注射術 (intracytoplasmic sperm injection;ICSI) 治療週期中,其會以重組濾泡刺激素 (recombinant follicle stimulating hormone;rFSH) 結合促性腺激素釋放激素 (gonadotrophin releasing hormone;GnRH) 類似物進行卵巢控制性超促排卵 (controlled ovarian hyperstimulation;COH) ,以預防早發性促黃體素 (luteinizing hormone;LH) 高峰之產生。然而,GnRH類似物之使用會使生長中之濾泡喪失LH。目前仍不清楚針對COH而以rLH與rFSH進行共投與之有效性。 比較在IVF或ICSI中於胚胎移植 (embryo transfer;ET) 後之COH程序中同時使用重組LH及重組FSH之與單獨使用重組FSH的有效性及安全性。 我們搜尋the MDSG Group Specialised Register (搜尋直到2006年11月) 以及CENTRAL、MEDLINE以及EMBASE (1980年2006年11月) 以及文章的參考資料清單。 比較在IVF/ICSI中以rFSH單獨進行COH或是結合rLH共同進行COH之隨機對照試驗。 由3位回顧作者獨立評估試驗品質並摘錄數據。在必要的情形下尋求額外之資訊。 共收錄涉及2612名婦女之14項試驗。其中涉及2396名婦女之11項試驗使用了GnRH激動劑。在其中2項試驗所報告之活產率中,並無具有統計上的差異 (OR 1.51, 95% CI 0.79 to 2.87) 。在其中7項試驗所報告之臨床懷孕率中,並無具有統計上的差異 (OR 1.15, 95% CI 0.91 to 1.45) 。在其中7項試驗所報告之繼續懷孕率中,並無具有統計差異之證據 (OR 1.22, 95% CI 0.95 to 1.56) 。其中3項試驗使用GnRH拮抗劑。並無有關活產率之數據。比較兩組,就臨床懷孕率 (1項試驗:OR 0.79, 95% CI 0.26 to 2.43) 或繼續懷孕率 (2項試驗: OR 0.83, 95% CI 0.39 to 1.80) 而言,其中並無統計差異之證據。由僅包括卵巢反應不佳病患之試驗取得的集合懷孕率估計值顯示,rLH之共投與可產生懷孕率的顯著增加 (3項試驗:OR 1.85, 95% CI 1.10 to 3.11) 。 在使用rLH時,懷孕率之結果並無具有統計差異之證據。然而,應以長期之GnRH激動劑減量調節程序進行進一步之大型RCTs,因為總和之懷孕率估計值可能因為數量過小而不具統計差異性,其皆指向rLH之共投與具有益作用,特別是就流產及卵巢反應不佳者而言。 此翻譯計畫由臺灣國家衛生研究院 (National Health Research Institutes, Taiwan) 統籌。 重組性促黃體素用於人工生殖週期中進行卵巢控制性超促排卵的情形 rLH 體外受精 (in vitro fertilization;IVF) 或精蟲卵質內注射術 (intracytoplasmic sperm injection;ICSI) 之標準治療為每日投皮下注射與重組濾泡刺激素 (recombinant follicle stimulating hormone;rFSH) 以在卵巢中誘發多濾泡生長,亦即所謂之卵巢控制性超促排卵 (controlled ovarian hyperstimulation;COH) 。此種治療會結合促性腺激素釋放激素 (gonadotrophin releasing hormone;GnRH) 激動劑或拮抗劑之每日皮下注射,其可對腦下垂體產生減量調節,預防早發性促黃體素 (luteinizing hormone;LH)...This publication has 34 references indexed in Scilit:
- Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive ageFertility and Sterility, 2006
- Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilizationFertility and Sterility, 2005
- Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniquesFertility and Sterility, 2004
- Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cyclesFertility and Sterility, 2004
- Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary downregulationClinical Endocrinology, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: More oocytes, more pregnancies. Results from five comparative studiesHuman Reproduction Update, 1996
- Pituitary and Ovarian Suppression After Early Follicular and Midluteal Administration of a Lhrh Agonist in a Depot Formulation: Decapeptyl CrGynecological Endocrinology, 1992
- INDUCTION OF OVULATION FOR IN-VITRO FERTILISATION USING BUSERELIN AND GONADOTROPINSThe Lancet, 1984
- STEROIDS IN THE FOLLICULAR FLUID AND THE CORPUS LUTEUM OF THE MARE. A 'TWO-CELL TYPE' THEORY OF OVARIAN STEROID SYNTHESISJournal of Endocrinology, 1962